Actively Recruiting
Nefecon and Ambrisentan in IgA Nephropathy
Led by The First Hospital of Jilin University · Updated on 2025-09-15
129
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and delaying eGFR progression, and observing changes in serum Gd-IgA1 levels
CONDITIONS
Official Title
Nefecon and Ambrisentan in IgA Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with IgA nephropathy by pathological biopsy within 4 years
- Age between 18 and 70 years old
- 24-hour urinary protein of at least 0.5 grams
- Estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m² or higher calculated by CKD-EPI formula
You will not qualify if you...
- Crescentic glomerulonephritis with more than 50% involvement, minimal change nephropathy with IgA deposits, or other special pathological kidney diseases
- Secondary IgA nephropathy from allergic purpura, ankylosing spondylitis, lupus, Sjogren's syndrome, viral hepatitis, cirrhosis, rheumatoid arthritis, or mixed connective tissue disease
- Cardiovascular events within 12 weeks before treatment including myocardial infarction, unstable angina, ventricular arrhythmia, heart failure NYHA class II or above, or stroke
- Use of systemic immunosuppressants or endothelin receptor antagonists within 12 weeks before treatment
- Active or untreated latent tuberculosis
- Active hepatitis or latent hepatitis B with positive HBV DNA or HBsAg positive
- Immunodeficiency diseases or positive HIV test
- Malignant tumors diagnosed within past 5 years except treated basal cell carcinoma, resected squamous cell carcinoma, colon polyps, or cervical cancer in situ
- Kidney transplant recipients
- Pregnant or breastfeeding women and those planning to conceive during the trial
- Allergy to human-derived biological products
- Participation in another clinical trial medication within 4 weeks before treatment
- Any condition deemed unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Hospital of Jilin University
Changchun, Jilin, China, 130021
Actively Recruiting
Research Team
W
Weixia Sun
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here